Advanced Search

 

Study ID Status Title Patient Level Data
PROA1010 Completed A Phase I, Open-label, Randomized, Balanced, Three period, Cross-over Study to Assess the Bioequivalence of a New 150 mg Soft Gelatin 141W94 Capsule With a Reduced TPGS Content Relative to the Original High TPGS Content 150 mg Soft Gelatin Capsule and to Assess the Effect of Food Upon the Oral B ...
PROA1011 Completed A phase I, open-label, randomized, balanced, three period, cross-over study to assess the oral bioavailability of the new 50 and 150 mg soft gelatin capsules relative to the new 141W94 (amprenavir) oral solution in healthy male subjects.
PROA1012 Completed A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Rifabutin and 141W94 and Rifampin Following Their Co-Administration to Healthy Male Volunteers.
PROA1013 Completed A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Clarithromycin Following Their Co-Administration to Healthy Male Volunteers.
PROAB3001 Completed A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination with RETROVIR and EPIVIR Compared to RETROVIR and EPIVIR Alone in Patients with HIV Infection.
PROAB3004 Completed A Phase III, Open Label Trial to Evaluate the Safety, Antiviral Efficacy and Pharmacokinetics of 141W94 Plus Current Therapy in HIV-1 Infected Children.
PROAB3006 Completed A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI Experienced, Protease Inhibitor (PI) Naïve HIV-1 Infected Patients
PROAB3007 Completed An open-label phase III study to assess the long term safety profile of amprenavir (141W94) containing regimens in HIV infected subjects
PROB1008 Completed A study to compare the pharmacokinetics of a single, oral, 600mg dose of amprenavir in healthy volunteers and patients with cirrhosis.
PROB2004 Completed A Phase II Trial to Assess the Preliminary Antiviral Effect, Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of APV Oral Solution in Combination with NRTIs in HIV Infected Children Below 13 Years Old
PROF3002 Completed Open label pilot study to evaluate the effect of antiretroviral drugs on HIV-1 in different compartments (plasma and lymphoid tissues).
R1810198 Completed An actual use study in support of the over-the-counter switch of Flonase Allergy
R1810220 Completed An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with perennial allergic rhinitis (PAR)
R1810221 Completed An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with seasonal allergic rhinitis (SAR)
RA1100849 Completed A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive protein (CRP) in subjects with rheumatoid arthritis (RA)
RA1104046 Completed A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship
RA3103718 Completed A randomized, double blind, placebo controlled study to investigate the safety and tolerability and clinical activity of 28 days of oral repeat dosing with GW856553 at 7.5mg BID in subjects with active rheumatoid arthritis on stable anti-rheumatic therapy.
RA3103730 Completed A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the C-Reactive Protein (CRP) dose response relationship
RA4104917 Completed A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects. Study Listed on ClinicalStudyDataRequest.com
RD 32/20370A H34(105)-121-V Completed Comparative bioavailability of 25mg and 100mg blackcurrant flavoured, dispersible lamotrigine tablets with 100mg lamotrigine capsules.
RD 32/20370B H34(105)-120-V Completed Comparative bioavailability of 5mg and 25mg black currant flavoured, dispersible lamotrigine tablets with 25mg lamotrigine capsules.
RES100767 Terminated A Study To Validate Key Therapeutic Targets and Characterise Their Response to Corticosteroids in Multiple Asthma Phenotypes
RES100769 Terminated A study to assess disease pathology and key therapeutic targets in severe asthma
RES104031 Completed A Randomised (with Respect to Microplaque Treatment Positions), Single-Blind, Placebo-Controlled, Positive-Controlled, Microplaque Study to Assess the Effectiveness of a Topical Formulation of GW786034 in Patients with Chronic Plaque Psoriasis
RES10983 Completed Double blind, randomised, placebo controlled, three periods, crossover study to investigate in a 72 hours enforced smoking cessation severity of withdrawal symptoms and craving in healthy volunteers on Zyban.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.